%0 Journal Article %T Th17细胞在非小细胞肺癌患者中的变化及可能机制探讨 %T Dynamic changes of Th17 cells in patients with non-small-cell lung cancer and its mechanisms %A 韦玉萍,段敏超,韩 伟,覃凤文,宁正庆,韦 球 %A WEI,Yu ping %A DUAN,Min chao %A HAN,Wei %A et al. %J 中国临床新医学 %J CHINESE JOURNAL OF NEW CLINICAL MEDICINE %@ 1674-3806 %V 10 %N 8 %D 2017 %P 730-734 %K 非小细胞肺癌;辅助性Th17细胞;白细胞介素类;流式细胞术 %K Non-small-cell lung cancer(NSCLC);T helper 17 cells;Interleukins;Flow cytometry %X [摘要] 目的 观察Th17细胞在非小细胞肺癌(NSCLC)患者外周血、癌灶组织及癌旁组织中的表达,探讨其临床意义及变化的可能机制。方法 选取30例NSCLC患者为肺癌组,20名健康体检者为对照组,应用流式细胞术检测肺癌组外周血、癌灶组织、癌旁组织以及对照组外周血中Th17(CD4+IL-17+)细胞的表达;免疫荧光定量PCR检测RORc mRNA、IL-17 mRNA水平;酶联免疫吸附法检测NSCLC患者血清、癌灶组织、癌旁组织以及对照组血清IL-6、IL-17、IL-23和转化生长因子β1(TGF-β1)浓度。分析NSCLC患者Th17细胞与临床病理类型及相关细胞因子水平的关系。结果 (1)NSCLC组外周血Th17细胞比例为(3.81±0.63)%,显著高于对照组的(0.73±0.22)%(P<0.001)。NSCLC组癌灶组织Th17细胞比例为(5.07±0.28)%,显著高于癌旁组织的(3.00±0.25)%及外周血(3.75±0.70)%(P均<0.001)。(2)NSCLC组外周血RORc mRNA及IL-17 mRNA分别为(3.91±0.48)和(68.91±6.31),均显著高于对照组(P均<0.001)。NSCLC组中癌灶组织RORc mRNA及IL-17 mRNA分别为(4.94±0.31)和(101.61±9.42),均显著高于癌旁组织[(2.35±0.21)、(46.02±4.11)]及外周血[(3.91±0.48)、(68.34±6.04)](P均<0.001)。(3)Ⅲ+Ⅳ期NSCLC患者外周血中Th17细胞比例(4.26±0.66)%及IL-17浓度(430.71±15.62)pg/ml显著高于Ⅰ+Ⅱ期患者(3.47±0.32)%和(368.09±20.74)pg/ml(P均<0.05)。Ⅲ+Ⅳ期NSCLC患者癌旁组织中Th17细胞比例(3.22±0.12)%及IL-17水平(268.98±19.67)pg/ml分别高于Ⅰ+Ⅱ期患者(2.83±0.18)%和(227.39±9.62)pg/ml(P<0.05)。Ⅲ+Ⅳ期NSCLC患者癌灶组织中Th17细胞比例为(5.33±0.48)%,IL-17浓度为(525.39±17.14)pg/ml,Ⅰ+Ⅱ期患者分别为(4.87±0.16)%和(462.50±22.67)pg/ml,两者差异无统计学意义(P均>0.05)。(4)NSCLC组患者血清IL-6、IL-17、IL-23和TGF-β1浓度显著高于对照组(P均<0.05)。NSCLC组患者癌灶组织IL-6、IL-17、IL-23和TGF-β1水平显著高于癌旁组织及血清(P<0.001)。(5)NSCLC患者外周血、癌灶组织Th17细胞比例与IL-6、IL-23和TGF-β1呈显著正相关关系(均P<0.01)。结论 NSCLC患者外周血、癌旁组织及癌灶组织中存在Th17细胞高表达,随病情进展有可能伴随高侵袭性及明显的血行转移;Th17细胞增高可能与IL-6、IL-23和TGF-β1的升高有关。 %X [Abstract] Objective To assess the variation of Th17 cells in peripheral blood, tumor and tumor-adjacent tissues in the patients with non-small-cell lung cancer(NSCLC) and to evaluate the correlation between their expressions and the clinicopathological features and to explore the probable mechanisms of its elevation.Methods Thirty NSCLC patients and twenty healthy controls were studied. All the samples of peripheral blood and tumor and tumor-adjacent tissues from 30 NSCLC patients were obtained. The proportions of Th17 cells in the peripheral blood, tumor tissues and tumor-adjacent tissues were evaluated by flow cytometry. The serum concentrations of IL-6, IL-17, IL-23 and TGF-β1 were measured by enzyme-linked immunosorbent assay(ELISA). The mRNA expressions of RORc and IL-17 in the peripheral blood, tumor tissues and tumor-adjacent tissues were examined by real-time quantitative polymerase chain reaction(QPCR).Results (1)The proportion of Th17 cells in the peripheral blood was significantly higher in the NSCLC patients (3.81±0.63)% than that in the healthy controls (0.73±0.22)%(P<0.001). The proportion of Th17 cells in the tumor tissues (5.07±0.28)% was significantly higher than that in their matched peripheral blood (3.75±0.70)% or tumor-adjacent tissues (3.00±0.25)%(P<0.001). (2)The levels of RORc mRNA (3.91±0.48) and IL-17 mRNA (68.91±6.31) in the peripheral blood were significantly higher in the NSCLC patients than those in the healthy controls(P<0.001). The levels of RORc mRNA (4.94±0.31) and IL-17 mRNA (101.61±9.42) in the tumor tissues were significantly higher than those in their matched peripheral blood [(3.91±0.48),(68.34±6.04)] or tumor-adjacent tissues[(2.35±0.21),(46.02±4.11)](P< 0.001). (3)The proportion of Th17 cells and the levels of IL-17 in peripheral blood and in tumor-adjacent tissues in the NSCLC patients with stage Ⅲ or Ⅳ were significantly higher than those in the patients with stage Ⅰ or Ⅱ(P<0.05). (4)The serum levels of IL-6, IL-17, IL-23 and TGF-β1 in the NSCLC patients were significantly higher than those in the healthy controls(P< 0.05). The levels of IL-6, IL-17, IL-23 and TGF-β1 in the tumor tissues were significantly higher than those in their matched peripheral blood and tumor-adjacent tissues(P<0.001).(5)The number of Th17 cells was significantly correlated with the levels of IL-6, IL-23 and TGF-β1 in the peripheral blood and tumor tissues from the NSCLC patients(P<0.01).Conclusion There are up-regulated expressions of Th17 in the peripheral blood, tumor and tumor-adjacent tissues from the NSCLC patients. With the progression of the disease, high invasion and migration into the circulation may exist. The elevated levels of IL-6, IL-23 and TGF-β may be related to the above effects. %R 10.3969/j.issn.1674-3806.2017.08.05 %U http://www.zglcxyxzz.com/ch/reader/view_abstract.aspx %1 JIS Version 3.0.0